NCT03713580View on ClinicalTrials.gov

Venetoclax in Combination With BEAM Conditioning Regimen for ASCT in Non-Hodgkin Lymphoma

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

March 12, 2019

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Non-hodgkin Lymphoma
Interventions
DRUG

Venetoclax

"Adding Venetoclax, a BCL-2 inhibitor, to standard high dose therapy prior to autologous stem cell transplant (ASCT).~Venetoclax is a novel, orally bioavailable, small-molecule B-cell lymphoma-2 (Bcl-2) family inhibitor."

Trial Locations (2)

44106

University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland

44195

Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center, Cleveland

All Listed Sponsors
lead

Case Comprehensive Cancer Center

OTHER